Skip to main content
Clinical Trials/RBR-67jth2z
RBR-67jth2z
Recruiting
Not Applicable

Evaluation of molecular and cellular markers for Tuberculosis diagnosis and prognosis

Instituto Gonçalo Moniz (IGM) da Fundação Oswaldo Cruz (FIOCRUZ)0 sitesOctober 9, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Instituto Gonçalo Moniz (IGM) da Fundação Oswaldo Cruz (FIOCRUZ)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 9, 2023
End Date
June 30, 2025
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Instituto Gonçalo Moniz (IGM) da Fundação Oswaldo Cruz (FIOCRUZ)

Eligibility Criteria

Inclusion Criteria

  • Participants with respiratory symptoms; men and women aged between 18 and 65 years (including) at the moment of informed consent; respiratory symptoms as a reason for seeking assistance at the Octávio Mangabeira Specialized Hospital (HEOM). Healthy participants; men and women aged between 18 and 65 years (inclusive) at the time of informed consent; postgraduate students, technicians, and/or researchers from the Gonçalo Moniz Institute (IGM), Fiocruz\-Ba; absence of respiratory symptoms or acute illnesses in the last 14 days.

Exclusion Criteria

  • Participants with respiratory symptoms; individuals under 18 years old and over 65 years old; using systemic corticosteroids; who have had a previous diagnosis and/or treatment for pulmonary TB in the last two years; transplant recipients, undergoing cancer treatment, or having autoimmune diseases. Healthy participants; presence of respiratory symptoms or acute illnesses in the last 14 days; previous diagnosis and/or treatment for pulmonary TB in the last two years

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Evaluation study of biological markers involved in cardiovascular diseases in childhoodcardiovascular diseases
JPRN-UMIN000002281Kyoto university100
Recruiting
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)Coronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecified
DRKS00022871CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover400
Completed
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-PROGRESS)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecified
DRKS00023277Charité – Universitätsmedizin Berlin, Med. Klinik m. S. Infektiologie und Pneumologie, und Arbeitsbereich Pulmonale Inflammation94
Completed
Not Applicable
Evaluation and molecular analysis of circulating tumor cells using the On-chip Sort for patients with non-small cell lung canceron-small cell lung cancer
JPRN-UMIN000012488Shizuoka Cancer Center30
Recruiting
Not Applicable
Evaluation of molecular markers to predict the pattern of tumor recurrence and prognosis in pancreatric ductal adenocarcinomaC25Malignant neoplasm of pancreas
DRKS00006179Klinik und Poliklinik für Allgemein-, Viszeral-, Tumor- und Transplantationschirurgie600